SG10201406651PA - A pharmaceutical composition for treating cancer comprising trypsinogen and/orchymotrypsinogen and an active agent selected from a selenium compound, a vanilloid compoundand a cytoplasmic glycolysis reduction agent - Google Patents
A pharmaceutical composition for treating cancer comprising trypsinogen and/orchymotrypsinogen and an active agent selected from a selenium compound, a vanilloid compoundand a cytoplasmic glycolysis reduction agentInfo
- Publication number
- SG10201406651PA SG10201406651PA SG10201406651PA SG10201406651PA SG10201406651PA SG 10201406651P A SG10201406651P A SG 10201406651PA SG 10201406651P A SG10201406651P A SG 10201406651PA SG 10201406651P A SG10201406651P A SG 10201406651PA SG 10201406651P A SG10201406651P A SG 10201406651PA
- Authority
- SG
- Singapore
- Prior art keywords
- orchymotrypsinogen
- compoundand
- trypsinogen
- vanilloid
- pharmaceutical composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4826—Trypsin (3.4.21.4) Chymotrypsin (3.4.21.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Inorganic Chemistry (AREA)
- Emergency Medicine (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2009905147A AU2009905147A0 (en) | 2009-10-22 | Pharmaceutical Compositions | |
| AU2010902655A AU2010902655A0 (en) | 2010-06-17 | Cancer Cell Regulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201406651PA true SG10201406651PA (en) | 2014-11-27 |
Family
ID=43899732
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201406651PA SG10201406651PA (en) | 2009-10-22 | 2010-10-22 | A pharmaceutical composition for treating cancer comprising trypsinogen and/orchymotrypsinogen and an active agent selected from a selenium compound, a vanilloid compoundand a cytoplasmic glycolysis reduction agent |
Country Status (22)
| Country | Link |
|---|---|
| US (4) | US9636359B2 (fr) |
| EP (2) | EP3095458B1 (fr) |
| JP (1) | JP5871805B2 (fr) |
| KR (1) | KR101936439B1 (fr) |
| CN (2) | CN107625957B (fr) |
| AU (1) | AU2010310887B9 (fr) |
| BR (1) | BR112012009521B1 (fr) |
| CA (1) | CA2814958C (fr) |
| CL (1) | CL2012001019A1 (fr) |
| DK (1) | DK3095458T3 (fr) |
| ES (1) | ES2692377T3 (fr) |
| HK (1) | HK1249017A1 (fr) |
| IL (1) | IL219216A (fr) |
| MX (1) | MX355971B (fr) |
| NZ (1) | NZ599996A (fr) |
| PE (1) | PE20121709A1 (fr) |
| PT (1) | PT3095458T (fr) |
| RU (1) | RU2012120785A (fr) |
| SG (1) | SG10201406651PA (fr) |
| TR (1) | TR201815315T4 (fr) |
| WO (1) | WO2011047434A1 (fr) |
| ZA (1) | ZA201203689B (fr) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107625957B (zh) | 2009-10-22 | 2021-06-15 | 普罗潘克股份有限公司 | 包含胰蛋白酶原和糜蛋白酶原的用于治疗癌的药物组合物 |
| CN114533753A (zh) * | 2013-03-15 | 2022-05-27 | 全技术公司 | 含硒组合物及其治疗和预防与线粒体功能障碍有关的疾病或病症的应用 |
| CZ307195B6 (cs) | 2013-11-18 | 2018-03-14 | František Trnka | Farmaceutická kompozice obsahující směs proenzymů a enzymů |
| US10201559B2 (en) * | 2014-03-14 | 2019-02-12 | Alltech, Inc. | Compositions of selenoorganic compounds and methods of use thereof |
| US10092550B2 (en) | 2014-10-21 | 2018-10-09 | Ions Pharmaceutical S.À R.L. | Therapeutic compositions containing curcumin, harmine, and isovanillin components, and methods of use thereof |
| US20160106722A1 (en) | 2014-10-21 | 2016-04-21 | Life Plus, LLC | Human therapeutic agents |
| US9907786B2 (en) | 2014-10-21 | 2018-03-06 | Ions Pharmaceutical S.À R.L. | Therapeutic compositions containing harmine and isovanillin components, and methods of use thereof |
| CA3003835A1 (fr) * | 2015-11-12 | 2017-05-18 | Propanc Pty Ltd | Composition de proenzyme |
| NZ744845A (en) | 2016-01-29 | 2023-04-28 | Propanc Pty Ltd | Cancer treatment |
| JP7004665B2 (ja) * | 2016-04-12 | 2022-02-04 | プロパンク・ピーティーワイ・リミテッド | 癌治療用の前酵素の組成物 |
| EP3517117A1 (fr) * | 2018-01-30 | 2019-07-31 | Medizinische Universität Wien | Médicament pour la prévention ou le traitement d'une infection par rhinovirus |
| WO2022261440A1 (fr) * | 2021-06-11 | 2022-12-15 | Sorrento Therapeutics, Inc. | Administration de résinifératoxine pour le traitement du cancer du pancréas |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4514388A (en) * | 1983-03-22 | 1985-04-30 | Psaledakis Nicholas G | Proteolytic enzymes in the zymogen form to treat sarcoma cells |
| US4978332A (en) * | 1987-09-28 | 1990-12-18 | Matrix Pharmaceutical, Inc. | Treatments employing vasoconstrictive substances in combination with cytotoxic agents for introduction into cellular lesion areas |
| US5595756A (en) * | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
| FR2727107B1 (fr) * | 1994-11-21 | 1996-12-27 | Saint Gobain Vitrage | Vitrage muni d'au moins une couche mince et son procede d'obtention |
| CZ283972B6 (cs) * | 1995-05-17 | 1998-07-15 | František Mudr. Trnka | Farmaceutický prostředek s modulačním účinkem na zhoubné nádory a jeho použití |
| CN1121218C (zh) * | 2000-03-08 | 2003-09-17 | 台湾东洋药品工业股份有限公司 | 酞胺哌啶酮在治疗肝细胞癌的药物组合物中的应用 |
| US6670330B1 (en) * | 2000-05-01 | 2003-12-30 | Theodore J. Lampidis | Cancer chemotherapy with 2-deoxy-D-glucose |
| WO2002056823A2 (fr) * | 2001-01-18 | 2002-07-25 | Arnold Hoffman | Therapie par oxydoreduction pour des tumeurs |
| CN1471925A (zh) * | 2002-08-02 | 2004-02-04 | 丛繁滋 | 更适于硬质肿瘤直接给药的含砷组合物、制剂及制备方法 |
| JP2004182674A (ja) * | 2002-12-05 | 2004-07-02 | Kureha Chem Ind Co Ltd | バニリル脂肪酸アミドを含む抗腫瘍医薬組成物 |
| CA2513399A1 (fr) * | 2003-01-10 | 2004-07-29 | Threshold Pharmaceuticals, Inc. | Traitement du cancer par le 2-desoxyglucose |
| CA2525277A1 (fr) * | 2003-05-13 | 2004-12-02 | Health Research Inc. | Procede pour augmenter l'activite antitumorale d'agents anticancereux |
| DE10321725A1 (de) * | 2003-05-14 | 2004-12-02 | Mucos Pharma Gmbh & Co | Enzymhaltige Zusammensetzungen, daraus hergestellte diätetische Lebensmittel und Arzneimittel und ihre Verwendung für medizinische Zwecke |
| CN1557482A (zh) * | 2004-02-04 | 2004-12-29 | 高春平 | 调节免疫功能、抗肿瘤的天然营养剂 |
| JP2006151965A (ja) * | 2004-10-28 | 2006-06-15 | Mi Tec:Kk | セレン含有組成物及びその製法 |
| WO2006126067A1 (fr) * | 2005-05-26 | 2006-11-30 | Council Of Scientific And Industrial Research | Composition pharmaceutique utile pour le traitement du carcinome hepatocellulaire |
| KR100740989B1 (ko) * | 2005-07-22 | 2007-07-19 | 넨시스(주) | 구형 항염·항암효소 과립제 및 이의 제조방법 |
| CN1944641B (zh) * | 2006-10-26 | 2010-11-03 | 上海林叶生物科技有限公司 | 高纯度糜蛋白酶的制备方法 |
| WO2009061051A1 (fr) * | 2007-11-09 | 2009-05-14 | Catholic University Industry Academic Cooperation Foundation | Nouvelle utilisation du capsiate ou du dihydrocapsiate |
| CN107625957B (zh) | 2009-10-22 | 2021-06-15 | 普罗潘克股份有限公司 | 包含胰蛋白酶原和糜蛋白酶原的用于治疗癌的药物组合物 |
| CZ307195B6 (cs) * | 2013-11-18 | 2018-03-14 | František Trnka | Farmaceutická kompozice obsahující směs proenzymů a enzymů |
-
2010
- 2010-10-22 CN CN201710885368.4A patent/CN107625957B/zh active Active
- 2010-10-22 EP EP16174383.6A patent/EP3095458B1/fr active Active
- 2010-10-22 ES ES16174383.6T patent/ES2692377T3/es active Active
- 2010-10-22 CA CA2814958A patent/CA2814958C/fr active Active
- 2010-10-22 US US13/502,917 patent/US9636359B2/en active Active
- 2010-10-22 SG SG10201406651PA patent/SG10201406651PA/en unknown
- 2010-10-22 PT PT16174383T patent/PT3095458T/pt unknown
- 2010-10-22 EP EP10824316A patent/EP2490711A4/fr not_active Withdrawn
- 2010-10-22 TR TR2018/15315T patent/TR201815315T4/tr unknown
- 2010-10-22 AU AU2010310887A patent/AU2010310887B9/en active Active
- 2010-10-22 JP JP2012534496A patent/JP5871805B2/ja active Active
- 2010-10-22 WO PCT/AU2010/001403 patent/WO2011047434A1/fr active Application Filing
- 2010-10-22 RU RU2012120785/15A patent/RU2012120785A/ru not_active Application Discontinuation
- 2010-10-22 PE PE2012000530A patent/PE20121709A1/es not_active Application Discontinuation
- 2010-10-22 NZ NZ599996A patent/NZ599996A/en unknown
- 2010-10-22 MX MX2012004610A patent/MX355971B/es active IP Right Grant
- 2010-10-22 DK DK16174383.6T patent/DK3095458T3/en active
- 2010-10-22 BR BR112012009521-8A patent/BR112012009521B1/pt active IP Right Grant
- 2010-10-22 KR KR1020127012943A patent/KR101936439B1/ko active IP Right Grant
- 2010-10-22 CN CN201080054056.5A patent/CN102639145B/zh active Active
-
2012
- 2012-04-16 IL IL219216A patent/IL219216A/en active IP Right Grant
- 2012-04-20 CL CL2012001019A patent/CL2012001019A1/es unknown
- 2012-05-21 ZA ZA2012/03689A patent/ZA201203689B/en unknown
-
2017
- 2017-03-17 US US15/462,655 patent/US10350239B2/en active Active
-
2018
- 2018-07-04 HK HK18108670.0A patent/HK1249017A1/zh unknown
-
2019
- 2019-05-31 US US16/428,581 patent/US20190388463A1/en not_active Abandoned
-
2022
- 2022-07-11 US US17/862,120 patent/US20230137573A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG10201406651PA (en) | A pharmaceutical composition for treating cancer comprising trypsinogen and/orchymotrypsinogen and an active agent selected from a selenium compound, a vanilloid compoundand a cytoplasmic glycolysis reduction agent | |
| LTPA2020520I1 (lt) | Anti-CD38 plius kortikosteroidai, plius nekortikosteroidinis chemoterapinis agentas, skirti vėžio gydymui | |
| IL255752B (en) | Compounds, pharmaceutical preparations containing the same uses for the treatment of cardiovascular disease, inflammatory diseases and cancer | |
| IL251637A0 (en) | Pd-1 pharmaceutical preparations containing an antagonist for the treatment of inflammations and tumors | |
| HK1204277A1 (en) | Compositions and methods for treating demodex infestations | |
| PL2532364T3 (pl) | Kompozycja farmaceutyczna zawierająca przeciwciała anty CAPRIN-1 do leczenia i/lub zapobiegania nowotworowi | |
| PL2532366T3 (pl) | Kompozycja farmaceutyczna do leczenia i/lub zapobiegania nowotworowi | |
| IL197121A0 (en) | Systems for programmable delivery of an active agent | |
| BRPI0922475A2 (pt) | composto, composição farmacêutica , método para tratar câncer, e, uso de um composto. | |
| BRPI0720546A2 (pt) | Composto, inibidor, medicamento, agente antitumor, composição farmacêutica, método para tratar câncer, e, uso do composto | |
| ZA201209424B (en) | Method for delivering an active agent | |
| EP2093237A4 (fr) | Agent anticancéreux comprenant un anticorps anti-hb-egf en tant qu'ingrédient actif | |
| HK1200187A1 (en) | Humanized anti-epiregulin antibody, and cancer therapeutic agent comprising said antibody as active ingredient | |
| IL205401A0 (en) | An orally - absorbed solid dose formulation for vancomycin | |
| IL197212A0 (en) | Methods for treating cancer comprising the administration of a vitamin d compound and an additional therapeutic agent, and compositions containing the same | |
| PL2327672T3 (pl) | Materiał na bazie zaprawy gipsowej zawierający środek zdolny do zatrzymywania formaldehydu | |
| BRPI0908635A2 (pt) | composto, composição farmacêutica e método de tratamento de câncer | |
| GB201003815D0 (en) | Low toxicity topical active agent delivery system | |
| BRPI1007334A2 (pt) | composto, inibidor, medicamento, composição farmacêutica, uso de um composto, agente anticâncer,e , método para tratar câncer. | |
| HK1162138A1 (en) | Skin-whitening agent, anti-aging agent, and anti-oxidant agent | |
| IL222707B (en) | Steroid compounds of 16-chloro- and 16, 16-dichloro-(4-alpha, 4-beta)-17-beta-(2-oxo-2h-pyran-5-yl) and pharmaceutical preparations containing them | |
| EP2910246A4 (fr) | Composition pharmaceutique pour la prévention ou le traitement du cancer, contenant enoblock comme principe actif | |
| EP2473506A4 (fr) | Composés et compositions pour le traitement du cancer | |
| PL2379056T3 (pl) | Stała kompozycja farmaceutyczna zawierająca co najmniej jeden środek stabilizujący | |
| EP2150243A4 (fr) | Compositions et procédés d'amélioration de l'absorption d'agents actifs |